Statins are associated with reduced risk of gastric cancer: A systematic review and meta-analysis

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1721-1730

  Singh, P P ^a   Singh, S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer risk; Chemoprevention; Gastric cancer; Statins

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ASIAN; CANCER PREVENTION; CANCER RISK; CAUCASIAN; DOSE RESPONSE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT DURATION;

CANCER RISK; CHEMOPREVENTION; GASTRIC CANCER; STATINS;

ANIMALS; ANTICARCINOGENIC AGENTS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84883771761     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt150     Document Type: Review

References (46)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Lello E, Furnes B, Edna TH. Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years. Acta Oncol 2007; 46: 308-315.
3. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
4. Cunningham SC, Kamangar F, Kim MP et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 2005; 9: 718-725.
5. Vakil N, Talley N, van Zanten SV et al. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol 2009; 7: 756-761.
6. Singh S, Singh PP, Singh AG et al. Statins are associated with a reduced risk of hepatocellular cancer: a Systematic review and meta-analysis. Gastroenterology 2012; 144: 323-332.
7. Bansal D, Undela K, D'Cruz S et al. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 2012; 7: e46691.
8. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-1802.
9. Demierre MF, Higgins PD, Gruber SB et al. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-942.
10. Follet J, Corcos L, Baffet G et al. The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis. Br J Cancer 2012; 106: 685-692.
11. Chiu HF, Ho SC, Chang CC et al. Statins are associated with a reduced risk of gastric cancer: a population-based case-control study. Am J Gastroenterol 2011; 106: 2098-2103.
12. Lee J, Lee SH, Hur KY et al. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer 2012; 12: 596.
13. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-637.
14. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011; 11: 409.
15. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2012. Available at www.cochrane-handbook.org (4 December 2012, date last accessed).
16. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
17. Wells GA SB, O'Connell D, Peterson J et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (10 December 2012, date last accessed).
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
19. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in metaanalyses. BMJ 2003; 327: 557-560.
20. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet 1991; 338: 1127-1130.
21. Guyatt GH, Oxman AD, Kunz R et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011; 64: 1294-1302.
22. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
23. Easterbrook PJ, Berlin JA, Gopalan R et al. Publication bias in clinical research. Lancet 1991; 337: 867-872.
24. Rosenthal R. The 'file drawer problem' and tolerance for null results. Psychol Bull 1979; 86: 638-641.
25. Emberson JR, Kearney PM, Blackwell L et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7: e29849.
26. Friedman GD, Flick ED, Udaltsova N et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008; 17: 27-36.
27. Graaf MR, Beiderbeck AB, Egberts AC et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-2394.
28. Haukka J, Sankila R, Klaukka T et al. Incidence of cancer and statin usage- record linkage study. Int J Cancer 2010; 126: 279-284.
29. Marelli C, Gunnarsson C, Ross S et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 2011; 58: 530-537.
30. Matsushita Y, Sugihara M, Kaburagi J et al. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf 2010; 19: 196-202.
31. Sato S, Ajiki W, Kobayashi T et al. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 2006; 16: 201-206.
32. Leung HW, Chan AL, Lo D et al. Common cancer risk and statins: a populationbased case-control study in a Chinese population. Expert Opin Drug Saf 2013; 12: 19-27.
33. Abnet CC, Freedman ND, Kamangar F et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009; 100: 551-557.
34. Wang WH, Huang JQ, Zheng GF et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95: 1784-1791.
35. Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol 2007; 102: 1789-1798.
36. Singh S, Singh AG, Singh PP et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, January 26 [epub ahead of print], doi:10.1016/j.cgh.2012.12.036.
37. Bonovas S, Filioussi K, Flordellis CS et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25: 3462-3468.
38. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-2132.
39. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004; 157: 327-349.
40. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 2008; 266: 99-115.
41. Cao Z, Fan-Minogue H, Bellovin DI et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 2011; 71: 2286-2297.
42. Patrick AR, Shrank WH, Glynn RJ et al. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health 2011; 14: 513-520.
43. Lee YC, Chen TH, Chiu HM et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013; 62: 676-682.
44. Ford AC, Moayyedi P. Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med 2009; 151: 513. author reply 513-514.
45. Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121-128.
46. Kato K, Gong J, Iwama H et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11: 549-560.